Papers/PMID:31118582
Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis.
Drug design, development and therapy2019The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
spironolactone — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Treatment with spironolactone was associated with a significant reduction in all-cause mortality [OR=0.4, 95%CI (0.24, 0.66), P=0.0003].”
Quoted verbatim from Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis.. - Study
- meta-analysis
- Population
- Adult patients with end-stage renal disease on hemodialysis, low-dose spironolactone added to conventional treatment versus control, pooled from randomised and non-randomised trials
Effect 0.4 odds ratio, 95% CI 0.24 to 0.66
Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: a meta-analysis.2019PMID:31118582Permalink